SRPT Sarepta Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 5, 2026SRPT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
SRPT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 12 lipca 2012 | 1-for-6 | Odwrotny |
O Sarepta Therapeutics, Inc. - Common Stock Przegląd firmy z Wikipedii
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
History
Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.
In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.
In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later.
The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001).
In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit.
In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS. The layoffs are part of a restructuring effort expected to generate around $400 million in cost savings by 2026.
Products
Its primary products are based on Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, originally developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos can also work as splice-switching oligos, targeting pre-mRNA to alter splicing and so causing changes in the structure of the mature mRNA (the mechanism of the approved drug eteplirsen). Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, treatment of some mutations causing Duchenne muscular dystrophy (DMD), and inhibition of infectious diseases. Their greatest clinical and commercial success thus far has been in the treatment of DMD. A new class of Morpholino oligos, the peptide-linked Morpholinos or PPMO, are linked to an arginine-rich cell-penetrating peptide to enhance their delivery into cells and have entered clinical trials.
The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, was approved as a human therapeutic by the FDA in 2016 and antisense oligonucleotides for Morpholinos targeting other exons are also subsequently approved. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile virus, SARS, hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection.
In December 2019, golodirsen (Vyondys 53) received US FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. The other approved PMO developed by Sarepta is casimersen (AMONDYS45) which is indicated for the treatment of DMD in patients amendable by exon 45 skipping.
In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
In 2019, Sarepta signed a licensing agreement with Roche for the development, and commercialization outside of USA, for SRP-9001. In June 2023, ELEVIDYS (Delandistrogene moxeparvovec) was approved by the FDA for use in 4-5-year-old boys with mutations in the DMD gene. The FDA granted accelerated approval to ELEVIDYS, which requires that the product be further studied to verify its clinical benefit.
In June 2024, the U.S. Food and Drug Administration expanded approval of delandistrogene moxeparvovec to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | SRPT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -10.9średnia z 5 lat ≈-0.3 | ≈-0.3 | · | · | |
| P/S (TTM) | 0.9średnia z 5 lat ≈7.6 | ≈7.6 | 31.2 | Niedowartościowany | |
| P/B (MRQ) | 1.2średnia z 5 lat ≈11.7 | ≈11.7 | 4.7 | Niedowartościowany | |
| Cena / FCF (TTM) | 22.6średnia z 5 lat ≈-21.1 | ≈-21.1 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 16.7średnia z 5 lat ≈-27.8 | ≈-27.8 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 1.2średnia z 5 lat ≈11.9 | ≈11.9 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | SRPT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | -7.3%średnia z 5 lat ≈-33.0% | ≈-33.0% | -701.6% | Najwyższa półka | |
| Marża EBITDA (TTM) | -5.0%średnia z 5 lat ≈-29.5% | ≈-29.5% | -701.6% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | -6.6%średnia z 5 lat ≈-38.7% | ≈-38.7% | -713.3% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | -6.9%średnia z 5 lat ≈-39.6% | ≈-39.6% | -660.8% | Najwyższa półka | |
| ROA (TTM) | -4.0%średnia z 5 lat ≈-13.2% | ≈-13.2% | -36.5% | Najwyższa półka | |
| ROE (TTM) | -9.5%średnia z 5 lat ≈-67.7% | ≈-67.7% | -59.5% | Zgodnie z | |
| ROIC | -62.3%średnia z 5 lat ≈-53.9% | ≈-53.9% | -63.3% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | SRPT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Wskaźnik bieżący (MRQ) | 4.4średnia z 5 lat ≈4.1 | ≈4.1 | 7.2 | Niska płynność | |
| Wskaźnik Szybkości (MRQ) | 2.3średnia z 5 lat ≈3.1 | ≈3.1 | 4.9 | Niska płynność | |
| Interest Coverage (Pokrycie odsetek) | 18.3średnia z 5 lat ≈-4.6 | ≈-4.6 | -76.8 | Silna płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | SRPT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 15.6%średnia z 5 lat ≈32.9% | ≈32.9% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 33.1%średnia z 5 lat ≈34.8% | ≈34.8% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 32.4% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | SRPT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.6średnia z 5 lat ≈0.4 | ≈0.4 | 0.1 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 0.0 | · | · | · | |
| Receivables Turnover (Rotacja należności) | 4.4średnia z 5 lat ≈4.6 | ≈4.6 | 7.5 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$2.6M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 4, 2026 | $-0.05 | $0.26 | -119.0% |
| 31 marca 2026 | $2.88 | $1.01 | 184.7% | |
| 31 grudnia 2025 | $-3.93 | $-1.26 | -213.0% | |
| 30 września 2025 | $-0.01 | $-0.83 | 98.8% | |
| 30 czerwca 2025 | $1.89 | $0.77 | 146.8% | |
| 31 marca 2025 | $-4.60 | $-0.97 | -376.2% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Cost of Revenue | $26M | · | · | · | · | · | · | · | · | $130.0K | · | · | |
| R&D Expense | · | · | · | · | · | · | · | $402M | $167M | $188M | $146M | $94M | |
| SG&A Expense | $492M | $558M | $482M | $451M | $283M | $318M | $285M | $208M | $123M | $84M | $75M | $49M | |
| Operating Expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $645M | $326M | $272M | $221M | $144M | |
| Operating Income | $-700M | $218M | $-268M | $-536M | $-460M | $-564M | $-706M | $-344M | $-172M | $-267M | $-220M | $-134M | |
| Interest Expense | $-38M | $-18M | $-22M | $-53M | $64M | $60M | $31M | $34M | $6M | $2M | $1M | · | |
| Interest Income | $31M | $31M | $36M | $16M | $354.0K | $3M | $7M | $7M | $2M | $507.0K | $890.0K | · | |
| Other Non-op | $-19M | $43M | $33M | $-28M | $-61M | $11M | $-236.0K | $-656.0K | $601.0K | $930.0K | $154.0K | $779.0K | |
| Pretax Income | $-702M | $261M | $-520M | $-690M | $-419M | $-553M | $-714M | $-363M | $-49M | $-267M | $-220M | · | |
| Income Tax | $11M | $26M | $16M | $14M | $-168.0K | $1M | $1M | $-692.0K | $2M | · | · | · | |
| Net Income | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| EPS (Basic) | $-7.13 | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| Shares (Basic) | 100,120,000 | 95,075,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | 48,697,000 | 42,290,000 | 40,026,000 | |
| Shares (Diluted) | 100,120,000 | 107,875,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | · | · | · | |
| EBITDA | $-655M | $256M | $-223M | $-494M | $-422M | $-537M | $-675M | $-331M | $-164M | $-261M | · | $-130M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $801M | $1.10B | $428M | $967M | $2.12B | $1.50B | $835M | $371M | $600M | $122M | $80M | $74M | |
| Short-term Investments | $138M | $252M | $1.25B | $1.02B | $0 | $436M | $290M | $803M | $479M | $195M | $112M | $137M | |
| Receivables | $398M | $602M | $400M | $215M | $153M | $101M | $91M | $49M | $29M | $5M | $4M | $2M | |
| Inventory | $915M | $750M | $323M | $204M | $186M | $232M | $171M | $125M | $84M | $13M | · | · | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | $1M | $3M | $3M | |
| Other Current Assets | $172M | $90M | $78M | $150M | $149M | $213M | $82M | $78M | $37M | $27M | $17M | $35M | |
| Current Assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373M | $225M | $248M | |
| PP&E (Net) | $345M | $340M | $227M | $180M | $191M | $190M | $130M | $97M | $43M | $38M | $37M | $39M | |
| PP&E (Gross) | $626M | $574M | $418M | $329M | $304M | $266M | $181M | $125M | $61M | $68M | $62M | $58M | |
| Accum. Depreciation | $280M | $234M | $191M | $149M | $113M | $76M | $51M | $28M | $18M | $30M | $25M | $20M | |
| Intangibles | $29M | $27M | $30M | $8M | $14M | $14M | $12M | $12M | $14M | $8M | $7M | $6M | |
| Other Non-current Assets | $156M | $80M | $137M | $163M | $293M | $204M | $174M | $107M | $22M | $4M | $4M | $2M | |
| Total Assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Accounts Payable | $281M | $214M | $165M | $96M | $77M | $111M | $68M | $34M | $8M | $30M | $20M | $12M | |
| Accrued Liabilities | $360M | $374M | $315M | $419M | $272M | $194M | $186M | $134M | $69M | $31M | $29M | $17M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Current Liabilities | $1.10B | $732M | $654M | $620M | $453M | $416M | $265M | $174M | $88M | $75M | $62M | $37M | |
| Capital Leases | $199M | $192M | $141M | $58M | $42M | $80M | $48M | · | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $3M | $42.0K | $11M | $20M | $5M | $16M | $6M | $6M | $6M | $7M | |
| Total Liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $610M | $519M | $87M | $83M | $47M | |
| Long-term Debt | $829M | $1.14B | $1.24B | $1.54B | $564M | · | · | $421M | $431M | $18M | $27M | $7M | |
| Total Debt | · | $0 | $105M | · | · | · | · | · | · | · | · | $4M | |
| Common Stock | $11.0K | $10.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $927M | |
| Retained Earnings | $-4.88B | $-4.21B | $-4.45B | $-3.91B | $-3.21B | $-2.85B | $-2.29B | $-1.58B | $-1.22B | $-1.17B | $-899M | $-679M | |
| Treasury Stock | $25M | $0 | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $272.0K | $-218.0K | $918.0K | $-2M | $-20.0K | $3.0K | $50.0K | $-99.0K | $-379.0K | $-120.0K | $-111.0K | $-95.0K | |
| Stockholders' Equity | $1.14B | $1.53B | $859M | $385M | $928M | $762M | $818M | $1.03B | $789M | $337M | $190M | $248M | |
| Liabilities + Equity | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Shares Outstanding | 104,964,220 | 96,900,496 | 93,731,831 | 87,950,117 | 87,126,974 | 79,374,247 | 75,184,863 | 71,071,887 | 64,791,670 | 54,759,234 | 45,629,529 | 41,311,512 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $45M | $38M | $44M | $42M | $38M | $27M | $24M | $12M | $8M | $6M | $5M | $4M | |
| Stock-based Comp | $123M | $184M | $183M | $233M | $114M | $108M | $79M | $50M | $30M | $30M | $32M | $20M | |
| Deferred Tax | $-363.0K | $-249.0K | $-165.0K | $-612.0K | $-309.0K | $-245.0K | $-376.0K | $-240.0K | · | · | · | · | |
| Amort. of Intangibles | $3M | $2M | $2M | $714.0K | $706.0K | $662.0K | $849.0K | $865.0K | $1M | $29.0K | · | · | |
| Restructuring | $42M | $0 | $0 | · | · | · | · | · | $3M | $4M | · | $14.0K | |
| Other Non-cash | $340M | $-663M | $-192M | $104M | $-176M | $527M | $150M | $-89M | $-220M | $-14M | · | $-17M | |
| Operating Cash Flow | $-205M | $-206M | $-501M | $-325M | $-443M | $107M | $-456M | $-389M | $-232M | $-246M | $-149M | $-129M | |
| CapEx | $102M | $137M | $76M | $31M | $38M | $82M | $60M | $61M | $12M | $5M | $3M | $25M | |
| Investing Cash Flow | $70M | $756M | $-166M | $-1.05B | $495M | $-122M | $287M | $-370M | $-179M | $-90M | · | · | |
| Debt Issued | · | · | · | $0 | $0 | $291M | $246M | · | $30M | · | $20M | · | |
| Net Debt Issued | · | · | · | $0 | · | $291M | · | · | $30M | · | · | $-94.0K | |
| Stock Issued | $20M | $0 | $0 | $0 | $0 | $312M | · | $513M | $354M | $365M | $120M | $95M | |
| Stock Repurchased | $25M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | · | $0 | · | $312M | $365M | $513M | $354M | $365M | · | · | |
| Financing Cash Flow | $-168M | $125M | $125M | $233M | $562M | $682M | $643M | $530M | $888M | $378M | · | · | |
| Net Change in Cash | $-304M | $675M | $-542M | $-1.14B | $614M | $668M | $473M | $-229M | $477M | $42M | $7M | $-183M | |
| Taxes Paid | $38M | $23M | $15M | $2M | $583.0K | $3M | $933.0K | $2M | $5M | · | · | · | |
| Free Cash Flow | $-307M | $-343M | $-577M | $-356M | $-482M | $25M | $-516M | $-450M | $-244M | $-251M | · | $-154M | |
| Levered FCF | $-269M | $-326M | $-600M | $-410M | $-545M | $-35M | $-547M | $-483M | $-250M | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% | · | · | |
| Net Margin | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% | · | · | |
| Pretax Margin | -31.9% | 13.7% | -41.8% | -74.0% | -59.7% | -102.4% | -187.5% | -120.4% | -31.5% | · | · | · | |
| EBITDA Margin | -29.8% | 13.5% | -18.0% | -53.0% | -60.1% | -99.5% | -177.2% | -110.1% | -105.8% | -4816.8% | · | · | |
| ROA | -19.5% | 6.5% | -16.8% | -22.4% | -13.7% | -23.1% | -41.3% | -24.5% | -5.9% | -76.6% | · | -46.3% | |
| ROE | -57.1% | 17.1% | -66.0% | -172.5% | -59.9% | -67.0% | -78.9% | -43.3% | -9.0% | -101.4% | · | -54.9% | |
| ROIC | -62.3% | 12.9% | -28.6% | -142.0% | -49.5% | -74.2% | -86.4% | -33.2% | -22.7% | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 | 6.0 | 5.5 | 8.2 | 13.9 | 5.0 | · | 6.7 | |
| Quick Ratio | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 | 4.9 | 4.6 | 7.0 | 12.5 | 4.3 | · | 5.8 | |
| Debt / Equity | · | 0.0 | 0.1 | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | 18.3 | -11.9 | -12.2 | -10.1 | -7.2 | -9.4 | -23.0 | -10.2 | -29.7 | · | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 | · | · | |
| Inventory Turnover | 0.0 | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Receivables Turnover | 4.4 | 3.8 | 4.0 | 5.1 | 5.5 | 5.6 | 5.4 | 7.7 | 8.9 | 1.2 | · | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $10.87 | $15.77 | $9.17 | $4.38 | $10.65 | $9.60 | $10.88 | $14.52 | $12.18 | $6.15 | · | $5.99 | |
| Revenue / Share | $21.96 | $17.63 | $13.46 | $10.66 | $8.64 | $6.93 | $5.17 | · | · | · | · | · | |
| Cash Flow / Share | $-2.05 | $-1.91 | $-5.42 | $-3.72 | $-5.45 | $1.38 | $-6.20 | · | · | · | · | · | |
| Cash / Share | $7.63 | $11.38 | $4.57 | $10.99 | $24.28 | $18.93 | $11.11 | $5.22 | $9.26 | $2.24 | · | $1.78 | |
| EPS (TTM) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-3.37 | $-3.37 | $-0.80 | · | $-6.37 | $-6.37 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 15.6% | 53.0% | 33.3% | 32.9% | 30.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 33.1% | 39.4% | 32.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 32.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Net Income TTM | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| Market Cap | $2.26B | $11.78B | $9.04B | $11.40B | $7.85B | $13.53B | $9.70B | $7.76B | $3.61B | $1.50B | · | $598M | |
| Enterprise Value | · | $10.43B | $7.47B | · | · | · | · | · | · | · | · | $391M | |
| P/E | -3.0 | 52.0 | -16.6 | -16.1 | -17.5 | -24.0 | -38.3 | -32.4 | -69.5 | · | -6.1 | -2.3 | |
| P/S | 1.0 | 6.2 | 7.3 | 12.2 | 11.2 | 25.1 | 25.5 | 25.8 | 23.3 | 277.1 | · | 61.3 | |
| P/B | 2.0 | 7.7 | 10.5 | 29.6 | 8.5 | 17.8 | 11.9 | 7.5 | 4.6 | 4.5 | · | 2.4 | |
| P / Tangible Book | 2.0 | 7.9 | 10.9 | 30.2 | 8.6 | 18.1 | · | · | · | · | · | · | |
| P / Cash Flow | -11.0 | -57.3 | -18.0 | -35.0 | -17.7 | 125.9 | -21.3 | -20.0 | -15.5 | -6.1 | · | -4.7 | |
| P / FCF | -7.3 | -34.4 | -15.7 | -32.0 | -16.3 | 535.6 | -18.8 | -17.2 | -14.8 | -6.0 | · | -3.9 | |
| EV / EBITDA | · | 40.8 | -33.4 | · | · | · | · | · | · | · | · | -3.0 | |
| EV / FCF | · | -30.4 | -12.9 | · | · | · | · | · | · | · | · | -2.5 | |
| EV / Revenue | · | 5.5 | 6.0 | · | · | · | · | · | · | · | · | 40.1 | |
| Earnings Yield | -33.1% | 1.9% | -6.0% | -6.2% | -5.7% | -4.2% | -2.6% | -3.1% | -1.4% | · | -16.5% | -44.0% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $401M | $731M | $443M | $399M | $611M | $745M | $658M | $467M | $363M | $413M | $397M | $332M | $261M | $254M | $258M | $230M | |
| Gross Profit | · | · | $-29M | $219M | $361M | $474M | $506M | $338M | $316M | $309M | · | · | · | · | · | · | |
| SG&A Expense | $108M | $109M | $128M | $92M | $138M | $134M | $164M | $128M | $139M | $127M | $132M | $121M | $119M | $111M | $120M | $105M | |
| Operating Expenses | $388M | $372M | $855M | $503M | $496M | $1.05B | $497M | $445M | $364M | $379M | $372M | $353M | $395M | $392M | $365M | $362M | |
| Operating Income | $13M | $358M | $-412M | $-103M | $116M | $-300M | $162M | $22M | $-701.0K | $35M | $25M | $-21M | $-134M | $-138M | $-107M | $-131M | |
| Interest Expense | $-22M | $-22M | $-46M | $2M | $-5M | $-5M | $-24M | $5M | $5M | $-4M | $-39M | $5M | $5M | $6M | $-100M | $15M | |
| Interest Income | $6M | $6M | $8M | $7M | $5M | $10M | $8M | $8M | $8M | $7M | $9M | $10M | $8M | $9M | $9M | $5M | |
| Other Non-op | $-15M | $-15M | $-22M | $48M | $38M | $-83M | $10M | $12M | $14M | $7M | $16M | $-12M | $17M | $13M | $6M | $378.0K | |
| Pretax Income | $-2M | $343M | $-278M | $-194M | $154M | $-384M | $172M | $34M | $14M | $41M | $40M | $-33M | $-15M | $-513M | $-101M | $-256M | |
| Income Tax | $3M | $12M | $5M | $-14M | $-43M | $64M | $13M | $395.0K | $7M | $5M | $-5M | $8M | $9M | $4M | $8M | $1M | |
| Net Income | $-5M | $331M | $-412M | $-51M | $197M | $-448M | $159M | $34M | $6M | $36M | $46M | $-41M | $-24M | $-517M | $-109M | $-258M | |
| EPS (Basic) | $-0.05 | $3.15 | $-3.93 | $-0.50 | $2.01 | $-4.60 | $1.65 | $0.35 | $0.07 | $0.38 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| EPS (Diluted) | $-0.05 | $2.88 | $-3.93 | $-0.50 | $1.89 | $-4.60 | $1.50 | $0.34 | $0.07 | $0.37 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| Shares (Basic) | 105,431,000 | 104,988,000 | · | 100,237,000 | 98,005,000 | 97,362,000 | · | 95,390,000 | 94,618,000 | 93,991,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| Shares (Diluted) | 105,431,000 | 121,916,000 | · | 100,237,000 | 106,623,000 | 97,362,000 | · | 100,448,000 | 99,144,000 | 99,114,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| EBITDA | $13M | $369M | · | $-103M | $116M | $-290M | · | $22M | $-701.0K | $44M | · | $-21M | $-134M | $-127M | · | $-131M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $571M | $464M | $801M | $613M | $511M | $241M | $1.10B | $198M | $384M | $427M | $428M | $542M | $852M | $872M | $967M | $1.04B | |
| Short-term Investments | $217M | $189M | $138M | $238M | $290M | $282M | $252M | $1.00B | $1.08B | $963M | · | $1.19B | $1.01B | $1.01B | · | $1.03B | |
| Receivables | $377M | $395M | $398M | $396M | $527M | $659M | $602M | $435M | $360M | $379M | · | $319M | $237M | $224M | · | $202M | |
| Inventory | $904M | $1.00B | $915M | $1.08B | $994M | $941M | $750M | $566M | $486M | $374M | · | $244M | $227M | $203M | · | $221M | |
| Other Current Assets | $106M | $188M | $172M | $192M | $128M | $105M | $90M | $165M | $75M | $83M | · | $154M | $148M | $180M | · | $131M | |
| Current Assets | $2.22B | $2.31B | $2.54B | $2.72B | $2.66B | $2.43B | $3.07B | $2.69B | $2.68B | $2.46B | · | $2.45B | $2.47B | $2.49B | · | $2.63B | |
| PP&E (Net) | $326M | $336M | $345M | $359M | $372M | $361M | $340M | $306M | $276M | $249M | · | $212M | $189M | $183M | · | $181M | |
| PP&E (Gross) | · | · | $626M | · | · | · | $574M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $280M | · | · | · | $234M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $31M | $31M | $29M | $30M | $31M | $26M | $27M | $28M | $28M | $29M | · | $20M | $18M | $7M | · | $13M | |
| Other Non-current Assets | $146M | $152M | $156M | $73M | $83M | $81M | $80M | $84M | $136M | $176M | · | $137M | $163M | $162M | · | $293M | |
| Total Assets | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Accounts Payable | $51M | $70M | $281M | $94M | $137M | $156M | $214M | $119M | $107M | $92M | · | $88M | $110M | $107M | · | $118M | |
| Accrued Liabilities | $325M | $302M | $360M | $296M | $377M | $392M | $374M | $345M | $350M | $283M | · | $322M | $327M | $346M | · | $369M | |
| Current Liabilities | $503M | $499M | $1.10B | $921M | $920M | $606M | $732M | $699M | $688M | $609M | · | $451M | $499M | $537M | · | $603M | |
| Capital Leases | $198M | $199M | $199M | $215M | $214M | $205M | $192M | $170M | $144M | $140M | · | $135M | $129M | $54M | · | $35M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $1M | $1M | $927.0K | $2M | $1M | $7M | $8M | · | $0 | $38.0K | $38.0K | · | $0 | |
| Total Liabilities | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B | $2.38B | $2.35B | $2.26B | · | $2.35B | $2.38B | $2.35B | · | $2.73B | |
| Long-term Debt | $848M | $838M | $829M | $1.04B | · | · | $1.14B | $1.23B | $1.23B | $1.24B | · | $1.24B | $1.24B | $1.23B | · | $1.54B | |
| Total Debt | · | · | · | · | · | · | · | $92M | $92M | $106M | · | · | · | · | · | · | |
| Common Stock | $11.0K | $11.0K | $11.0K | $11.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | · | $9.0K | $9.0K | $9.0K | · | $9.0K | |
| Retained Earnings | $-4.55B | $-4.55B | $-4.88B | $-4.64B | $-4.46B | $-4.66B | $-4.21B | $-4.37B | $-4.40B | $-4.41B | · | $-4.49B | $-4.45B | $-4.43B | · | $-3.80B | |
| Treasury Stock | $25M | $25M | $25M | $25M | $25M | · | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $-565.0K | $-121.0K | $272.0K | $220.0K | $-51.0K | $34.0K | $-218.0K | $2M | $-1M | $-691.0K | · | $-638.0K | $-1M | $-419.0K | · | $-3M | |
| Stockholders' Equity | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B | $1.53B | $1.22B | $1.08B | $961M | $859M | $764M | $741M | $713M | $385M | $431M | |
| Liabilities + Equity | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Shares Outstanding | 105,623,500 | 105,571,146 | 104,964,220 | 104,768,111 | 97,706,074 | 98,254,898 | 96,900,496 | 95,493,005 | 95,282,600 | 94,490,157 | · | 93,537,355 | 93,273,541 | 93,140,135 | · | 87,766,199 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $11M | $5M | $18M | $11M | $10M | $10M | $10M | $9M | $9M | $11M | $11M | $11M | $11M | $11M | $11M | |
| Stock-based Comp | $24M | $29M | $30M | $15M | $37M | $41M | $50M | $43M | $50M | $41M | $46M | $48M | $47M | $41M | $51M | $50M | |
| Amort. of Intangibles | $717.0K | $691.0K | $677.0K | $677.0K | $667.0K | $601.0K | $601.0K | $602.0K | $601.0K | $601.0K | $763.0K | $439.0K | $179.0K | $178.0K | $179.0K | $178.0K | |
| Restructuring | · | · | $1M | $41M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-574M | · | · | · | $-187M | · | · | · | $-328M | · | · | · | $255M | · | · | |
| Operating Cash Flow | $197M | $-203M | $131M | $-15M | $261M | $-583M | $92M | $-71M | $15M | $-242M | $-55M | $-115M | $-122M | $-209M | $-92M | $-65M | |
| CapEx | $555.0K | $2M | $4M | $23M | $32M | $44M | $38M | $37M | $29M | $32M | $19M | $30M | $18M | $9M | $8M | $8M | |
| Investing Cash Flow | $-93M | $-134M | $96M | $232M | $32M | $-291M | $764M | $-129M | $-99M | $219M | $-64M | $-211M | $97M | $12M | $10M | $19M | |
| Stock Issued | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $0 | $241.0K | $-39M | $-118M | $-24M | $12M | $49M | $14M | $40M | $22M | $2M | $15M | $6M | $102M | $11M | $216M | |
| Net Change in Cash | $104M | $-337M | $188M | $100M | $270M | $-862M | $905M | $-186M | $-44M | $-1M | $-117M | $-310M | $-20M | $-95M | $-72M | $171M | |
| Taxes Paid | $8M | $2M | $16M | $1M | $19M | $835.0K | $11M | $4M | $7M | $909.0K | $6M | $4M | $5M | $535.0K | $339.0K | · | |
| Free Cash Flow | · | $-205M | · | · | · | $-627M | · | · | · | $-275M | · | · | · | $-219M | · | · | |
| Levered FCF | · | $-184M | · | · | · | $-622M | · | · | · | $-278M | · | · | · | $-225M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3.3% | 49.0% | · | -25.9% | 18.9% | -40.3% | · | 4.8% | -0.19% | 8.4% | · | -6.3% | -51.1% | -54.5% | · | -57.0% | |
| Net Margin | -1.2% | 45.3% | · | -45.1% | 32.2% | -60.1% | · | 7.2% | 1.8% | 8.7% | · | -12.3% | -9.2% | -203.8% | · | -111.9% | |
| Pretax Margin | -0.44% | 47.0% | · | -48.6% | 25.1% | -51.5% | · | 7.3% | 3.7% | 10.0% | · | -10.0% | -5.6% | -202.2% | · | -111.4% | |
| EBITDA Margin | 3.3% | 50.5% | · | -25.9% | 18.9% | -39.0% | · | 4.8% | -0.19% | 10.6% | · | -6.3% | -51.1% | -50.0% | · | -57.0% | |
| ROA | -0.14% | 10.0% | · | -5.1% | 5.5% | -13.4% | · | 1.0% | 0.20% | 1.1% | · | -1.3% | -0.78% | -16.9% | · | -8.9% | |
| ROE | -0.34% | 25.0% | · | -14.2% | 16.2% | -42.5% | · | 3.4% | 0.71% | 4.3% | · | -6.9% | -3.3% | -65.8% | · | -57.2% | |
| ROIC | 2.4% | 23.0% | · | -7.3% | 10.9% | -30.7% | · | 1.7% | -0.03% | 2.9% | · | -3.4% | -29.6% | -19.5% | · | -30.6% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.4 | 4.6 | · | 3.0 | 2.9 | 4.0 | · | 3.8 | 3.9 | 4.0 | · | 5.4 | 5.0 | 4.6 | · | 4.4 | |
| Quick Ratio | 2.3 | 2.1 | · | 1.4 | 1.4 | 2.0 | · | 2.3 | 2.6 | 2.9 | · | 4.6 | 4.2 | 3.9 | · | 3.8 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | -0.6 | -16.5 | · | -13.7 | 22.1 | 66.7 | · | 4.5 | -0.1 | 8.4 | · | -4.0 | -25.6 | -21.8 | · | -8.9 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.2 | · | 0.1 | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.9 | 1.4 | · | 1.0 | 1.4 | 1.4 | · | 1.2 | 1.2 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.3 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $14.46 | $14.26 | · | $12.60 | $13.89 | $11.63 | · | $12.79 | $11.30 | $10.17 | · | $8.17 | $7.95 | $7.65 | · | $4.91 | |
| Revenue / Share | $3.81 | $5.99 | · | $3.98 | $5.73 | $7.65 | · | $4.65 | $3.66 | $4.17 | · | $3.73 | $2.94 | $2.87 | · | $2627.80 | |
| Cash Flow / Share | · | $-1.66 | · | · | · | $-5.99 | · | · | · | $-2.44 | · | · | · | $-2.37 | · | · | |
| Cash / Share | $5.41 | $4.40 | · | $5.85 | $5.23 | $2.45 | · | $2.07 | $4.03 | $4.52 | · | $5.79 | $9.13 | $9.36 | · | $11.83 | |
| EPS (TTM) | $-1.60 | $0.34 | · | $-1.71 | $-0.87 | $-2.69 | · | $1.57 | $0.77 | $0.43 | · | $-7.83 | $-10.31 | $-12.69 | · | $-8.22 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.97B | $2.18B | · | $2.41B | $2.48B | $2.23B | · | $1.64B | $1.50B | $1.40B | · | $1.10B | $1.00B | $976M | · | $876M | |
| Net Income TTM | $-137M | $65M | · | $-142M | $-58M | $-248M | · | $122M | $47M | $17M | · | $-691M | $-908M | $-1.12B | · | $-716M | |
| Market Cap | $1.90B | $2.30B | · | $2.02B | $1.67B | $6.27B | · | $11.93B | $15.05B | $12.23B | · | $11.34B | $10.68B | $12.84B | · | $9.70B | |
| Enterprise Value | · | · | · | · | · | · | · | $10.82B | $13.69B | $10.95B | · | · | · | · | · | · | |
| P/E | -11.2 | 64.0 | · | -11.3 | -19.7 | -23.7 | · | 79.5 | 205.2 | 301.1 | · | -15.5 | -11.1 | -10.9 | · | -13.4 | |
| P/S | 1.0 | 1.1 | · | 0.8 | 0.7 | 2.8 | · | 7.3 | 10.0 | 8.7 | · | 10.3 | 10.6 | 13.2 | · | 11.1 | |
| P/B | 1.2 | 1.5 | · | 1.5 | 1.2 | 5.5 | · | 9.8 | 14.0 | 12.7 | · | 14.8 | 14.4 | 18.0 | · | 22.5 | |
| P / Tangible Book | 1.3 | 1.6 | · | 1.6 | 1.3 | 5.6 | · | 10.0 | 14.4 | 13.1 | · | 15.2 | 14.8 | 18.2 | · | 23.2 | |
| P / Cash Flow | · | -11.3 | · | · | · | -10.7 | · | · | · | -50.5 | · | · | · | -61.3 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | 6.6 | 9.1 | 7.8 | · | · | · | · | · | · | |
| Earnings Yield | -8.9% | 1.6% | · | -8.9% | -5.1% | -4.2% | · | 1.3% | 0.49% | 0.33% | · | -6.5% | -9.0% | -9.2% | · | -7.4% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $2.20B | $1.90B | $1.24B | $933M | $702M |
| Marża Operacyjna % | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% |
| Zysk netto | $-713M | $235M | $-536M | $-703M | $-419M |
| Rozwodniony EPS | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | · | 0.0 | 0.1 | · | · |
| Wskaźnik bieżący | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 |
| Wskaźnik Szybkości | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-307M | $-343M | $-577M | $-356M | $-482M |
Właściciele instytucjonalni (13F) 367 emitentów · $2.3B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 50 (-9 vs poprzedni kw.) | 60 (+14 vs poprzedni kw.) | 101 (-10 vs poprzedni kw.) | 125 (-17 vs poprzedni kw.) | +3.1M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $341 339 398 | 18 994 958 | 14,85% | Akcje |
| VANGUARD GROUP INC | $254 166 887 | 11 810 729 | 11,06% | Akcje |
| STATE STREET CORP | $160 222 137 | 8 916 090 | 6,97% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $150 543 136 | 8 377 470 | 6,55% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $82 639 268 | 4 598 735 | 3,60% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $82 513 837 | 4 591 755 | 3,59% | Akcje |
| FIRST TRUST ADVISORS LP | $78 456 086 | 4 365 951 | 3,41% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $76 867 492 | 4 325 689 | 3,35% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $49 818 796 | 2 771 758 | 2,17% | Akcje |
| Erste Asset Management GmbH | $45 513 625 | 2 568 945 | 1,98% | Akcje |
| TWO SIGMA ADVISERS, LP | $44 575 108 | 2 071 334 | 1,94% | Akcje |
| MARSHALL WACE, LLP | $39 642 216 | 2 206 022 | 1,73% | Akcje |
| MORGAN STANLEY | $39 581 468 | 2 202 641 | 1,72% | Akcje |
| Aberdeen Group plc | $39 443 216 | 2 194 948 | 1,72% | Akcje |
| BANK OF AMERICA CORP /DE/ | $36 946 051 | 2 055 985 | 1,61% | Akcje |
| GOLDMAN SACHS GROUP INC | $36 703 734 | 2 042 501 | 1,60% | Akcje |
| UBS Group AG | $29 190 737 | 1 624 415 | 1,27% | Akcje |
| FEDERATED HERMES, INC. | $28 578 248 | 1 590 331 | 1,24% | Akcje |
| LMR Partners LLP | $25 021 428 | 1 392 400 | 1,09% | Opcja sprzedaży |
| CITADEL ADVISORS LLC | $23 727 588 | 1 320 400 | 1,03% | Opcja kupna |
| NORTHERN TRUST CORP | $21 756 855 | 1 210 732 | 0,95% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $21 446 620 | 1 193 468 | 0,93% | Akcje |
| CITIGROUP INC | $20 755 457 | 1 155 006 | 0,90% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $20 151 163 | 1 121 378 | 0,88% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17 616 368 | 980 321 | 0,77% | Akcje |
| Connor, Clark & Lunn Investment Management Ltd. | $17 493 669 | 973 493 | 0,76% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16 823 514 | 936 200 | 0,73% | Opcja sprzedaży |
| Invesco Ltd. | $16 233 721 | 903 379 | 0,71% | Akcje |
| Legal & General Group Plc | $15 770 961 | 877 627 | 0,69% | Akcje |
| 683 Capital Management, LLC | $14 061 525 | 782 500 | 0,61% | Akcje |
| Bank of New York Mellon Corp | $13 911 725 | 774 164 | 0,61% | Akcje |
| ADAR1 Capital Management, LLC | $13 129 763 | 730 649 | 0,57% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $12 640 823 | 703 629 | 0,55% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $12 548 685 | 698 313 | 0,55% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $12 240 212 | 681 147 | 0,53% | Akcje |
| Jump Financial, LLC | $12 209 627 | 679 445 | 0,53% | Akcje |
| Voleon Capital Management LP | $12 116 183 | 674 245 | 0,53% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12 059 667 | 671 100 | 0,52% | Opcja kupna |
| Qube Research & Technologies Ltd | $10 958 034 | 609 796 | 0,48% | Akcje |
| MACKENZIE FINANCIAL CORP | $10 774 381 | 599 576 | 0,47% | Akcje |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $10 165 988 | 565 720 | 0,44% | Akcje |
| JPMORGAN CHASE & CO | $9 345 699 | 544 392 | 0,41% | Akcje |
| Point72 Asset Management, L.P. | $9 181 017 | 510 908 | 0,40% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $9 175 572 | 510 605 | 0,40% | Akcje |
| Casdin Capital, LLC | $8 445 900 | 470 000 | 0,37% | Akcje |
| Assenagon Asset Management S.A. | $8 165 119 | 454 375 | 0,36% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $8 120 068 | 451 868 | 0,35% | Akcje |
| Hudson Bay Capital Management LP | $8 086 500 | 450 000 | 0,35% | Akcje |
| Man Group plc | $7 154 647 | 398 144 | 0,31% | Akcje |
| PRUDENTIAL FINANCIAL INC | $7 083 235 | 394 170 | 0,31% | Akcje |
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Richard J. Barry (2) | 5 maja 2015 | · | Pierwotne zgłoszenie | · | SEC |
| George W. Haywood, Cheryl Haywood, Rockall Emerging Markets Master Fund Ltd., Meldrum Asset Management, LLC, Con Egan, Conor O’Driscoll ×2 zgłoszenia | 22 kwietnia 2010 | · | Pierwotne zgłoszenie | · | SEC |
| Eastbourne Capital Management, L.L.C., Richard Jon Barry, Black Bear Offshore Master Fund, L.P., Black Bear Fund I, L.P., Black Bear Fund II, L.L.C. ×4 zgłoszenia | 8 marca 2010 | · | Pierwotne zgłoszenie | · | SEC |
| Medtronic, Inc., Medtronic International, Ltd. | 14 lutego 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 8 stycznia 2002 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 29 czerwca 2001 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 65 insiderów · 29 dyrektorzy generalni · 18 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Severino | Chief Executive Officer | 28 lipca 2026 A | 756 104 | 0 | 0 | $0 |
| Douglas S Ingram | Chief Executive Officer | 7 grudnia 2025 A | 929 391 | 0 | 0 | $0 |
| David J Boyle II | CEO | 27 sierpnia 2010 P | 70 282 | 0 | 0 | $0 |
| Leslie Hudson | Former CEO | 30 lipca 2010 M | 384 559 | 0 | 0 | $0 |
| Denis R Burger | Chief Executive Officer | 3 kwietnia 2007 A | 151 717 | 0 | 0 | $0 |
| Ryan Ho-Yan Wong | Chief Financial Officer | 4 września 2026 F | 121 792 | 0 | 0 | $0 |
| Sandesh Mahatme | EVP, CFO & CBO | 8 lipca 2020 M | 20 260 | 0 | 0 | $0 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | 4 września 2026 F | 203 900 | 0 | 0 | $0 |
| Ian Michael Estepan | Chief Operating Officer | 4 września 2026 F | 177 184 | 0 | 1 | $-294 202 |
| Cristin Rothfuss | EVP, General Counsel | 4 września 2026 F | 115 519 | 0 | 0 | $0 |
| Bilal Arif | Chief Tech Ops Officer | 5 sierpnia 2025 A | 32 500 | 0 | 0 | $0 |
| Dallan Murray | Chief Customer Officer | 10 marca 2025 A | 38 202 | 0 | 0 | $0 |
| Ryan Edward Brown | EVP, General Counsel | 25 czerwca 2024 M | 17 129 | 0 | 0 | $0 |
| William Ciambrone | EVP | 7 marca 2022 A | 22 099 | 0 | 0 | $0 |
| Joseph Bratica | Principal Financial Officer | 11 grudnia 2020 M | 8 140 | 0 | 0 | $0 |
| David T Howton | EVP, General Counsel | 22 czerwca 2020 M | 31 871 | 0 | 0 | $0 |
| Alexander Cumbo | EVP, Chief Commercial Officer | 28 lutego 2020 A | 8 567 | 0 | 0 | $0 |
| Shamim Ruff | SVP, Chief Regulatory Affairs | 22 maja 2018 M | 31 936 | 0 | 0 | $0 |
| Guriqbal S. Basi | SVP, Chief Scientific Officer | 5 marca 2018 A | · | 0 | 0 | $0 |
| Arthur M Krieg | SVP, Chief Scientific Officer | 13 stycznia 2014 A | · | 0 | 0 | $0 |
| Michael A Jacobsen | VP of Finance and PAO | 23 sierpnia 2012 A | 7 500 | 0 | 0 | $0 |
| Bracha Ephrat Toshav | Sr VP & General Counsel | 31 sierpnia 2011 A | · | 0 | 0 | $0 |
| Melinda G Mile | Controller and PAO | 31 sierpnia 2011 A | · | 0 | 0 | $0 |
| Peter S Linsley | SVP & Chief Scientific Officer | 16 maja 2011 A | · | 0 | 0 | $0 |
| Graham Johnson | Sr VP Preclinical Dev & Rsrch | 23 sierpnia 2010 A | · | 0 | 0 | $0 |
| Paul Medeiros | SVP Business Development | 23 sierpnia 2010 A | · | 0 | 0 | $0 |
| Stephen B Shrewsbury | SVP/Regulatory Affairs | 23 sierpnia 2010 A | 60 000 | 0 | 0 | $0 |
| Patrick L Iversen | Sr VP of Research & Devlopment | 23 sierpnia 2010 A | 86 303 | 0 | 0 | $0 |
| Dwight D Weller | Sr. VP Chemistry & Mfg. | 23 sierpnia 2010 A | 314 741 | 0 | 0 | $0 |
| Michael Andrew Chambers | Dyrektor | 4 czerwca 2026 A | 27 535 | 0 | 0 | $0 |
| Stephen Mayo | Dyrektor | 4 czerwca 2026 A | 18 640 | 0 | 1 | $-123 208 |
| Kathryn Jean Boor | Dyrektor | 4 czerwca 2026 A | 25 138 | 0 | 0 | $0 |
| Claude Nicaise | Dyrektor | 4 czerwca 2026 A | 48 407 | 0 | 0 | $0 |
| Richard Barry | Dyrektor | 4 czerwca 2026 A | 2 983 542 | 0 | 0 | $0 |
| Hans Lennart Rudolf Wigzell | Dyrektor | 4 czerwca 2026 A | 42 098 | 0 | 0 | $0 |
| Deirdre P Connelly | Dyrektor | 4 czerwca 2026 A | 22 100 | 0 | 0 | $0 |
| Kathleen M Behrens | Dyrektor | 4 czerwca 2026 A | 214 357 | 0 | 0 | $0 |
| Mary Ann Gray | Dyrektor | 7 marca 2022 A | 12 356 | 0 | 0 | $0 |
| John C Martin | Dyrektor | 3 marca 2021 A | 7 913 | 0 | 0 | $0 |
| Michael W Bonney | Dyrektor | 28 lutego 2020 A | 9 126 | 0 | 0 | $0 |
| Edward M. Kaye MD | Dyrektor | 3 sierpnia 2017 M | 71 229 | 0 | 0 | $0 |
| Jean-Paul Kress | Dyrektor | 10 marca 2017 A | 2 000 | 0 | 0 | $0 |
| Ben Gil Price | Dyrektor | 14 marca 2016 P | 42 830 | 0 | 0 | $0 |
| William Alden Goolsbee | Dyrektor | 29 lutego 2016 A | 8 166 | 0 | 0 | $0 |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | Posiadacz 10% | 4 marca 2010 S | 5 659 211 | 0 | 0 | $0 |
| MEDTRONIC INC | Posiadacz 10% | 25 maja 2004 S | 0 | 0 | 0 | $0 |
| Gilmore Neil O'Neill | · | 3 marca 2021 A | 28 546 | 0 | 0 | $0 |
| Catherine Stehman-Breen | · | 3 kwietnia 2017 A | · | 0 | 0 | $0 |
| Jayant Aphale | · | 19 września 2016 M | 11 490 | 0 | 0 | $0 |
| Nishan Garabedian Christopher | · | 27 lutego 2015 A | 29 552 | 0 | 0 | $0 |
| Anthony R Chase | · | 27 lutego 2015 A | 67 194 | 0 | 0 | $0 |
| John Hodgman | · | 27 lutego 2015 A | 6 333 | 0 | 0 | $0 |
| Anthony Martignetti | · | 4 czerwca 2013 A | · | 0 | 0 | $0 |
| Ryszard Kole | · | 9 lutego 2010 A | 1 862 926 | 0 | 0 | $0 |
| George Weaver Haywood | · | 25 sierpnia 2009 P | 8 213 717 | 0 | 0 | $0 |
| Michael D Casey | · | 19 maja 2009 A | 5 000 | 0 | 0 | $0 |
| FORREST K MICHAEL | · | 19 maja 2009 A | 15 000 | 0 | 0 | $0 |
| Christopher S Henney | · | 31 marca 2009 A | · | 0 | 0 | $0 |
| John W Fara PHD | · | 20 maja 2008 A | · | 0 | 0 | $0 |
| Peter D Ohanley | · | 28 lutego 2008 A | · | 0 | 0 | $0 |
| Mark Miles Webber | · | 28 lutego 2008 A | · | 0 | 0 | $0 |
| Alan P Timmins | · | 2 lutego 2008 J | · | 0 | 0 | $0 |
| James B Hicks | · | 22 maja 2007 A | 6 000 | 0 | 0 | $0 |
| Jack L Bowman | · | 22 maja 2007 A | 5 000 | 0 | 0 | $0 |
| Joseph B Horn | · | 22 marca 2006 A | · | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 56 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,67% | 620 211 SH | 1 października 2026 | Dziennie |
| IBRN · iShares Trust | 2,18% | 7 938 SH | 11 września 2026 | Dziennie |
| BBP · ETFis Series Trust I | 1,34% | 88 646 NS | 31 lipca 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,04% | 101 778 SH | 1 października 2026 | Dziennie |
| HAPS · Harbor ETF Trust | 0,81% | 92 720 NS | 31 lipca 2026 | N-PORT |
| XSHQ · Invesco Exchange-Traded Fund Trust … | 0,52% | 82 108 SH | 1 października 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,45% | 151 157 NS | 31 lipca 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,45% | 5 675 SH | 1 października 2026 | Dziennie |
| IBB · iShares Trust | 0,15% | 772 730 SH | 11 września 2026 | Dziennie |
| SMDX · Tidal Trust III | 0,15% | 13 054 NS | 31 lipca 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 64 607 SH | 19 sierpnia 2026 | Dziennie |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,13% | 76 657 SH | 19 sierpnia 2026 | Dziennie |
| ESSC · Strategy Shares | 0,13% | 3 094 NS | 31 lipca 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,13% | 2 065 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,13% | 7 460 SH | 1 października 2026 | Dziennie |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,12% | 15 261 SH | 1 października 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,11% | 84 228 SH | 19 sierpnia 2026 | Dziennie |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,11% | 95 830 NS | 31 lipca 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,11% | 113 549 SH | 1 października 2026 | Dziennie |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,10% | 369 221 SH | 19 sierpnia 2026 | Dziennie |
| VIOV · VANGUARD ADMIRAL FUNDS | 0,08% | 87 370 SH | 19 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,07% | 2 658 934 SH | 11 września 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,06% | 598 819 SH | 19 sierpnia 2026 | Dziennie |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 27 534 NS | 31 lipca 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,05% | 1 332 977 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,05% | 49 826 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,03% | 299 980 SH | 19 sierpnia 2026 | Dziennie |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,02% | 8 682 NS | 31 lipca 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 46 891 NS | 31 lipca 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 1 210 549 SH | 19 sierpnia 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2 292 990 SH | 19 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,02% | 6 093 SH | 11 września 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,02% | 6 769 NS | 31 lipca 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,01% | 68 063 SH | 1 października 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 772 SH | 19 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,01% | 67 657 SH | 11 września 2026 | Dziennie |
| TILT · FlexShares Trust | 0,01% | 13 904 NS | 31 lipca 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 83 934 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 11 994 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 8 729 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 141 450 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,00% | 37 436 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 25 570 SH | 11 września 2026 | Dziennie |
| DFAU · Dimensional ETF Trust | 0,00% | 22 144 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 65 871 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 3 187 072 SH | 19 sierpnia 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 80 332 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 8 458 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,00% | 23 052 SH | 19 sierpnia 2026 | Dziennie |
| IJR · iShares Trust | · | 6 444 975 SH | 10 września 2026 | Dziennie |
| IJT · iShares Trust | · | 613 122 SH | 9 września 2026 | Dziennie |
| IJS · iShares Trust | · | 369 121 SH | 8 września 2026 | Dziennie |
| IWN · iShares Trust | · | 910 181 SH | 11 września 2026 | Dziennie |
| XJR · iShares Trust | · | 14 552 SH | 31 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | · | 4 621 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 22 361 SH | 11 września 2026 | Dziennie |
SRPT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
22 analityków · 2026-10-03Średnia cel $21.73 +24,2%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| GENB | · | · | · | · | · | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.